Russia to seek approval for one-shot Sputnik Light in SA
Business Day reported on 14 October that Russia will seek authorisation from SA Health Products Regulatory Authority (SAHPRA) for its single-shot Sputnik Light coronavirus vaccine after a study showed it is 70% effective at preventing transmission of the Delta variant three months after inoculation. Sputnik Light is the first component of the two-shot Sputnik V vaccine, developed by the Gamaleya National Research Centre of Epidemiology and Microbiology with backing from the Russian Direct Investment Fund (RDIF). It has been authorised as a stand-alone vaccine in more than 15 countries, while Sputnik V has been approved in 70 countries. Russia has been struggling to get its vaccines approved by
the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency.